文 | 大V商业，作者丨贾志飞 3个月前，科沃斯在德国IFA上闪击石头科技，现在有了结果。 12月19日，UPC（欧洲统一专利法院）公布了一项判决，科沃斯在9月4号，也就是IFA期间，对石头科技提出的单方命令（ex-parte）审查申请属于违法行 为，予以撤销。 事情发生在德国柏林IFA（知名国际无线电展览会）期间，欧洲市场纷繁复杂并且与国内截然不同的专利保护策略，导致这场调查成为了一场乌龙案。 （UPC的判决书） UPC的紧急保护机制被滥用 先说一下事件的双方都发生了什么。 科沃斯和石头科技作为国内知名的扫地机企业，双方近几年出海欧洲并占据了不小的市场份额。 2025 IFA期间，科沃斯以石头科技侵犯其EP3808512专利，向UPC申请证据保全。 这里要普及几个知识点。 首先，什么是UPC。 UPC的全称是Unified Patent Court（欧洲统一专利法院），是一个专门为欧盟成员国设立的超国家法院（Supranational Court）。它的建立是为了解决长期 以来欧洲专利诉讼分散在各个国家法院（如德国法院、法国法院等）的问题。 其对涉及欧洲市场的专利具有超越德国、法国、英国本国法院的管辖权，简 ...

Core Viewpoint - The company, Shunluo Electronics, has filed a lawsuit against Murata Manufacturing Co., Ltd. for maliciously initiating a patent infringement lawsuit, which has been accepted by the Shanghai Intellectual Property Court [1][3] Group 1: Lawsuit Details - Shunluo Electronics has made four specific requests in the lawsuit: 1. To confirm that Murata's previous patent infringement lawsuit constitutes malicious litigation 2. To seek compensation for economic losses amounting to 1.5 million RMB 3. To require Murata to publicly apologize in Chinese, Japanese, and English on its official website and designated media to mitigate the impact 4. To have Murata bear the litigation costs [3] Group 2: Company Position - The company asserts that Murata's prior lawsuit lacks a legitimate basis or shows clear malice, forcing Shunluo Electronics to allocate resources to respond, thus prompting this counter-suit to protect its legal rights [3] - The company emphasizes that the ongoing case has not yet gone to trial, making it impossible to accurately predict its impact on profits, with the final outcome dependent on the court's ruling [3] - The lawsuit is characterized as a legitimate measure to counter suspected malicious litigation and will not affect the company's normal production and operations [3] Group 3: Industry Implications - This counter-suit signifies an escalation of the previous patent infringement dispute initiated by Murata, with the court's recognition of "malicious litigation" expected to be a focal point of industry attention [3]

Core Viewpoint - Whirlpool has filed a complaint with the U.S. International Trade Commission (ITC) to block the import and sale of microwaves produced by competitors such as Samsung and LG, claiming these products infringe on its patented technology [1] Group 1: Company Actions - Whirlpool is seeking to protect its market by alleging that its competitors have copied its patented technology related to low-profile microwave hood combination products (LP-MHC) [1] - The company asserts that it was the sole supplier of LP-MHC products in the U.S. before the alleged infringement began [1] Group 2: Competitors - The complaint specifically targets South Korean competitors Samsung and LG for infringing on five of Whirlpool's patents [1] - Whirlpool emphasizes its role in creating the LP-MHC product category, highlighting its innovation in this market segment [1]

Core Points - The U.S. International Trade Commission has initiated a new investigation to determine whether the import of Apple's latest smartwatch should be banned due to a patent dispute with Masimo Corporation [1] - The investigation will assess if Apple's smartwatch infringes on Masimo's patents related to blood oxygen measurement technology, with a decision expected within six months [1] - Apple claims the lawsuit is baseless and aims to hinder the launch of its blood oxygen detection feature, alleging that Masimo is attempting to copy Apple's smartwatch design [1] Group 1 - A federal jury in California recently ruled that Apple infringed on a Masimo patent, awarding Masimo $634 million in damages [1] - In 2023, the Commission prohibited the import of Apple's Series 9 and Ultra 2 smartwatches after finding that Masimo's patents were infringed, leading Apple to remove the blood oxygen detection technology from its devices to avoid the ban [1] - In August, Apple updated the blood oxygen feature for certain Apple Watch models after receiving approval from U.S. Customs and Border Protection, despite Masimo's lawsuit against the agency [2] Group 2 - A California judge declared Masimo's trade secret case against Apple as "invalid" due to a hung jury [2] - Last year, Apple won a minor victory in Delaware, receiving $250 in a counterclaim against Masimo, which was accused of infringing on two of Apple's design patents [2]

Core Points - A California federal jury ruled that Apple infringed on Masimo's patents related to blood oxygen detection technology in the Apple Watch, ordering Apple to pay approximately $634 million in damages [1][3] - Apple plans to appeal the ruling, while Masimo views the decision as a significant victory for protecting its innovations and intellectual property [1] Legal Disputes - The ruling is part of a long-standing patent dispute, with Masimo previously accusing Apple of poaching key employees and misappropriating pulse oximetry technology for the Apple Watch [3] - In 2023, the U.S. International Trade Commission (ITC) found Apple guilty of infringement, leading to an import ban on the Apple Watch Series 9 and Ultra 2 [3] - To comply with the import ban, Apple temporarily removed the blood oxygen detection feature from its products until a revised version was approved by U.S. Customs and Border Protection in August [3] Ongoing Legal Proceedings - The ITC announced it will initiate a new process to review whether the updated Apple Watch still falls under the import ban [3] - Masimo's lawsuit regarding the customs approval decision is still pending, and Apple has appealed the previous import ban to the federal appeals court [3] - The companies have engaged in multiple legal battles, including a failed commercial secrets lawsuit in California in 2023 and a symbolic $250 judgment in Delaware in 2024 favoring Apple [3]

Core Viewpoint - The U.S. International Trade Commission has initiated a new proceeding to assess whether imports of Apple's updated Apple Watches should be banned due to a patent dispute with a medical technology company [1] Group 1: Legal Proceedings - The decision to hold a new proceeding indicates ongoing legal challenges faced by Apple in relation to its product imports [1] - The patent dispute highlights the competitive landscape in the technology and medical sectors, where intellectual property rights are increasingly contested [1] Group 2: Market Implications - A potential ban on Apple Watch imports could significantly impact Apple's market presence and sales in the wearables segment [1] - The outcome of this proceeding may set a precedent for future patent disputes involving technology companies and their product lines [1]

Core Viewpoint - Transsion, known as the "king of African mobile phones," is facing significant challenges due to increased competition and rising costs, leading to a situation of "increased revenue but decreased profit" [4][21]. Group 1: Company Background and Growth - Transsion was founded in 2006 by Zhur Zhaojiang, who identified the potential of the African market after extensive travel [5]. - The company achieved remarkable success, becoming the top mobile phone vendor in Africa by 2017, with a market share exceeding 40% by 2024 [7][8]. - Transsion's unique innovations, such as deep skin tone beautification technology, catered specifically to African consumers, contributing to its rapid market capture [5][7]. Group 2: Financial Performance - In the first three quarters of 2025, Transsion reported revenue of 495.4 billion yuan, a slight decline of 3.3% year-on-year, while net profit plummeted nearly 45% to 21.5 billion yuan [4][13]. - Despite a revenue rebound in Q3 2025, net profit still fell by 11.06% to 9.35 billion yuan [4][13]. - The company's gross margin decreased to 19.5%, and net margin dropped from 7.69% to 4.47% in 2025 [12][13]. Group 3: Competitive Landscape - Transsion's market dominance is being challenged by competitors like Xiaomi, Huawei, OPPO, and vivo, who are aggressively entering the African market [9][12]. - The competitive landscape has shifted from growth to intense competition, with Transsion's market share growth slowing to 6% in Q2 2025 [12]. - The entry of these competitors has led to a significant erosion of Transsion's traditional low-end market segment [9][12]. Group 4: Cost Pressures and Legal Challenges - Rising costs, particularly in memory chips, have severely impacted Transsion's profit margins, with prices for DDR4 memory increasing over 100% [16][17]. - The company is also embroiled in ongoing patent disputes, notably with Huawei, which has further complicated its operational landscape [17]. - Sales expenses increased by 4.17% in the first three quarters of 2025, further squeezing profit margins [17]. Group 5: Strategic Responses - In response to declining profits, Transsion is focusing on product upgrades and increasing R&D spending, which rose by 17.26% to 2.139 billion yuan in 2025 [15][16]. - The company is diversifying its market presence by exploring opportunities in South Asia and Latin America, as well as expanding into digital accessories and home appliances [15][16]. - Despite these efforts, new business segments are still in the investment phase and have not yet made a significant contribution to overall revenue [15].

Core Viewpoint - The patent dispute between BeiGene and Pharmacyclics LLC has concluded, with Pharmacyclics deciding not to appeal the final decision from the USPTO, marking a significant resolution for BeiGene's flagship product, Zebrutinib, which has achieved over $1 billion in global sales in 2023 [2][4][5]. Group 1: Patent Dispute Resolution - Pharmacyclics LLC, a subsidiary of AbbVie, has opted not to appeal the USPTO's decision regarding the patent dispute with BeiGene, allowing both parties to voluntarily withdraw the lawsuit filed in 2023 [2][3]. - The lawsuit claimed that BeiGene's Zebrutinib infringed upon Pharmacyclics' patent rights, specifically the "803 patent," which was granted in June 2023, just seven months after Zebrutinib's market approval [4][5]. - The USPTO ruled that the claims of the "803 patent" were overly broad and lacked inventiveness, leading to its invalidation, which has now been finalized with the withdrawal of the lawsuit [5]. Group 2: Financial Impact and Market Position - Zebrutinib, a BTK inhibitor developed by BeiGene, was the first innovative drug from China to be approved in the U.S. based on Chinese clinical data, achieving sales of $1.3 billion in 2023 [4][5]. - The resolution of the patent dispute is crucial as over 51.86% of BeiGene's revenue in the first half of 2023 came from the U.S. market, making it the company's largest revenue source [5]. Group 3: Ongoing Patent Risks - Despite the resolution of the Zebrutinib patent case, BeiGene still faces ongoing patent litigation from AbbVie regarding another compound, BGB-16673, which has received priority drug designation from the EMA [3][6]. - The company has stated its intention to vigorously defend against these allegations and has filed a motion to dismiss the lawsuit set for December 2024 [6]. Group 4: Industry Context - The patent dispute highlights the increasing patent risks faced by Chinese pharmaceutical companies as they expand internationally, with 4.1% of the pharmaceutical manufacturing sector encountering intellectual property disputes abroad [7][9]. - Recent reports indicate that 22 out of 29 new patent litigation cases involving Chinese biopharmaceutical companies were filed in the U.S., underscoring the challenges in navigating international patent laws [7][8].

Core Insights - Amgen's stock price rose by 5.78% on October 1, marking a total increase of 10.07% over four consecutive days, reaching its highest level since August 2025, which has generated positive investor sentiment regarding its future market performance [1] - The stock price increase is partly attributed to recent policy interactions between the U.S. government and the pharmaceutical industry, including a drug pricing agreement between the Trump administration and Pfizer, which has provided favorable conditions for large pharmaceutical companies like Amgen [1] - Amgen has resolved a patent dispute with Bicon, avoiding potential legal risks and stabilizing market confidence in the company [1] - The company announced a $650 million investment to expand its manufacturing capabilities in the U.S., particularly in Puerto Rico, which will significantly enhance its biopharmaceutical production capacity and create nearly 750 new jobs [1] Industry Context - The positive developments surrounding Amgen support its strong market performance, but investors should remain aware of potential challenges arising from policy changes in the pharmaceutical industry [2] - Policy uncertainty will continue to be a significant factor influencing future market trends, necessitating a cautious approach from investors when formulating strategies [2] - Continuous monitoring of industry trends and company developments is crucial for investors to identify stable investment opportunities amid market volatility [2]

Core Points - Masimo has filed a lawsuit against the U.S. Customs and Border Protection (CBP), alleging that CBP unlawfully allowed Apple to reinstate a blood oxygen monitoring feature on the Apple Watch that infringes on Masimo's patents [1] - The dispute stems from a 2023 ruling by the U.S. International Trade Commission, which found Apple guilty of patent infringement, leading to a suspension of certain Apple Watch sales [1] - On August 14, Apple announced a software update to restore the blood oxygen monitoring feature by shifting the calculation process to the paired iPhone instead of the watch itself [1] - Masimo claims it was unaware of CBP's unilateral decision made two weeks prior, which overturned an earlier ruling without consulting Masimo, violating standard procedures [1] - The lawsuit cites violations of the Administrative Procedure Act and the due process clause of the Fifth Amendment [1] Legal Actions - Masimo is seeking a temporary restraining order and a preliminary injunction to prevent the enforcement of CBP's August 1 ruling [2] - The company aims to restore the January decision, which was made with participation from both Apple and Masimo, stipulating that related products could only be imported if the blood oxygen monitoring feature was disabled [2]